Sign in
CompletedPhase 3

A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder.

Key facts

Who runs it
Luye Pharma Group Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
555 people enrolled
Started
4 Aug 2023
Ended
31 Jul 2025
Type of study
Interventional, 3 groupsOne group gets a sham (pretend) treatment, for comparison.
Treatments tested
  • Toludesvenlafaxine Hydrochloride Sustained-release Tablet 80mg
  • Toludesvenlafaxine Hydrochloride Sustained-release Tablet 160mg
  • placebo
Record updated
8 July 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Male or female aged 18 to 65 years subjects
  • Meet the Diagnostic and Statistical Manual of Manual Disorders, fifth Edition(DSM-5) criteria for Generalized Anxiety Disorder
  • Have a Hamilton Anxiety(HAMA) Rating Scale total score ≥21 points at screening and baseline
  • Have a Hamilton Anxiety(HAMA) Rating Scale score ≥2 points on both item 1(anxious mood) and item 2(tension) at screening and baseline
  • Have a clinical Global Impression -severity illness (CGI-S) score≥4 points at screening and baseline

Who cannot take part

  • Meet the diagnostic criteria for other psychotic disorders(defined by DSM-5, except for GAD), including major depression disorder within 6 months prior to screening , presence or history of Schizophrenia Spectrum and Other Psychotic Disorders, Bipolar and Related Disorders, Obsessive-Compulsive and related Disorders, post-traumatic stress disorder, anorexia nervosa or bulimia and personality disorder
  • Meet the diagnostic criteria for substance or alcohol abuse (defined by DSM-5, except for nicotine or caffeine) within 6 months prior to screening
  • Withdrawal psychotropic drugs within 5 half-lives (at least 2 weeks for monoamine oxidase inhibitors, at least 1 month for fluoxetine, and at least 2 weeks for benzodiazepines or barbiturates) prior to randomization
  • Have received psychosurgery or physical therapy for psychiatric illness (such as transcranial magnetic stimulation) within 3 months prior to screening
  • Have received systematic psychotherapy or other non-drug therapies for psychiatric disorders (such as acupuncture or light therapy) within 6 weeks prior to screening
  • Concomitant with serious and unstable illness, including cardiovascular, hepatic, renal, hematological, endocrine illness, malignant tumors and other physical illness
  • Have anxious symtoms secondary to other physical illnesses or mental illnesses and anxious induced by psychoactive substance
  • Have a history of seizures (except for seizures caused by febrile convulsions in childhood)
  • Have a history of gastrointestinal disease or surgery known to interfere with investigation product absorption or excretion
  • Known or suspected allergic or severe reaction to investigation product or inactive ingredients; or allergic to venlafaxine or desvenlafaxine; or allergic constitution (defined as allergic to two or more drugs or food) and unfit to participate judged by investigator

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The study aims to evaluate the efficacy and safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets compared to placebo in adults participants with generalized anxiety disorder over a period of 8 weeks.

The 3 groups in the trial

  • Toludesvenlafaxine Hydrochloride Sustained-release Tablets 80 mg groupTreatment being tested

    orally once a day

    Treatment: Toludesvenlafaxine Hydrochloride Sustained-release Tablet 80mg

  • Toludesvenlafaxine Hydrochloride Sustained-release Tablets 160 mg groupTreatment being tested

    orally once a day

    Treatment: Toludesvenlafaxine Hydrochloride Sustained-release Tablet 160mg

  • PlaceboSham treatment, for comparison

    orally once a day

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Participants With Generalized Anxiety Disorder.
Record updated
8 July 2026